This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

4. Leading National Epigenetic Therapy and Technology Markets 2013-2023

4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012

4.2 Leading National Markets: Revenue Forecasts 2013-2023

4.2.1 The Continued Dominance of Western Markets 2013-2023

4.3 The North American Market 2013-2023

4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023

4.3.2 Canada: Revenues 2013-2023

4.4 The European Market 2011-2012

4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023

4.4.2 Germany: Revenues 2013-2023

4.4.3 The UK: A Leading Market for Epigenetics Research

4.5 Japan: Recent Entry of the Epigenetic Therapies Market

4.6 Epigenetics in Emerging Markets

4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023

5. Epigenetic Therapies Market 2013-2023

5.1 Changes to the Epigenetic Therapies Market 2013-20235.2 Vidaza: The First Epigenetic Therapy Approved5.2.1 Vidaza: Strong Revenue Growth 2004-20115.2.2 Development as a Combination Therapy to Drive Growth5.2.3 Vidaza: Revenue Forecast 2013-20235.3 Dacogen5.3.1 Revenue Performance 2004-20115.3.2 Approval in the EU in 2012 to Drive Revenue Growth5.3.3 Dacogen: Revenue Forecast 2013-20235.4 Zolinza5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma5.4.2 Zolinza: Revenue Forecast 2013-20235.5 Istodax5.5.1 US PTCL Approval5.5.2 Istodax: Revenue Forecast 2013-20235.6 Rich Pipeline for HDAC Inhibitors in 20125.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL5.6.2 Faridak for Velcade-Refractory Multiple Myeloma5.6.3 Entinostat (Syndax Pharmaceuticals)5.6.4 Resminostat (4SC)5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials5.6.7 Quisinostat (Centocor Research & Development)5.6.8 Rocilinostat (Acetylon Pharmaceuticals)5.6.9 CHR-3996 (Chroma Therapeutics) 5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases5.6.11 SHP-141 (Shape Pharmaceuticals) 5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene) 5.6.13 4SC-202 (4SC) 5.6.14 Tefinostat (Chroma Therapeutics) 5.6.15 CXD101 (Celleron Therapeutics) 5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications5.6.17 Abexinostat (Pharmacyclics/Servier)5.7 DNMT Inhibitor Pipeline 20125.7.1 SGI-110: A Second Generation DNMT Inhibitor5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 20125.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor5.8.2 Oryzon Genomics: Targeting LSD15.8.3 Salarius Pharmaceuticals5.8.4 Resverlogix Advancing BET Protein Inhibitors5.9 MiRNA Therapy Pipeline 20125.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy5.9.2 MRX34 (Mirna Therapeutics)5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players5.10 Leading Epigenetic Therapy Manufacturers and Developers 20125.10.1 Celgene: Market Leader 2011-20125.10.2 Eisai5.10.3 Merck & Co.5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies5.10.5 Syndax Pharmaceuticals5.10.6 4SC5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer5.10.8 Curis is Developing Multi-Targeted Therapies5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development5.10.10 Constellation Pharmaceuticals5.10.11 EpiTherapeutics5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer

6. Epigenetic Diagnostics Market 2013-2023

6.1 Development of the Epigenetic Diagnostics Market 2013-2023

5 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs